Clinical Policy: Acitretin (Soriatane)
Reference Number: CP.PMN.40
Effective Date: 08.10
Last Review Date: 08.19
Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Acitretin (Soriatane®) is an aromatic, synthetic retinoid.

FDA Approved Indication(s)
Soriatane is indicated for the treatment of severe psoriasis in adults.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Soriatane is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Psoriasis (must meet all):
      1. Diagnosis of psoriasis;
      2. Prescribed by or in consultation with a dermatologist;
      3. Age ≥ 18 years;
      4. Member must meet one of the following (a, b, or c):
         a. Failure of ≥ 8 week trial of phototherapy in combination with methotrexate or cyclosporine;
         b. If contraindication to methotrexate and cyclosporine, failure of ≥ 8 weeks of phototherapy in combination with one of the following agents: a medium to high potency steroid, tazarotene, or calcipotriene, unless contraindicated or clinically significant adverse effects are experienced;
         c. If phototherapy is not available, failure of two of the following from different classes: a medium to high potency steroid, tazarotene, or calcipotriene each used for ≥ 8 weeks at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
      5. Dose does not exceed 50 mg (2 capsules) per day.
      Approval duration: 6 months

   B. Other diagnoses/indications
      1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.
II. Continued Therapy

A. Psoriasis (must meet all):
   1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   2. Member is responding positively to therapy;
   3. If request is for a dose increase, new dose does not exceed 50 mg (2 capsules) per day.

   Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

   Approval duration: Duration of request or 12 months (whichever is less); or
   2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

   Appendix A: Abbreviation/Acronym Key
   FDA: Food and Drug Administration

   Appendix B: Therapeutic Alternatives
   This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>methotrexate</td>
<td>10 to 25 mg PO/IV/IM as a single does weekly or 2.5 mg PO every 12 hours for 3 doses every week</td>
<td>30 mg/week</td>
</tr>
<tr>
<td>Topical corticosteroids</td>
<td>Varies</td>
<td>Varies</td>
</tr>
<tr>
<td>cyclosporine</td>
<td>1.25 mg/kg PO BID</td>
<td>Varies</td>
</tr>
<tr>
<td>tazarotene (Tazorac®)</td>
<td>Apply topically QD</td>
<td>1 application daily</td>
</tr>
<tr>
<td>calcipotriene</td>
<td>(Dovonex®)</td>
<td>100 g/week</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.
Appendix C: Contraindications/Boxed Warnings

- **Contraindication(s):**
  - Pregnancy
  - Use in patients with severely impaired liver or kidney function and in patients with chronic abnormally elevated blood lipid values.
  - Combination use with methotrexate: an increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate. Note: Tegison (etretinate) is no longer marketed in the U.S.
  - Combination use with tetracyclines: may cause increased intracranial pressure.
  - Cases of hypersensitivity (e.g., angioedema, urticaria) to the preparation (acitretin or excipients) or to other retinoids.

- **Boxed warning(s):**
  - Soriatane must not be used by females who are pregnant, or who intend to become pregnant during therapy or at any time for at least 3 years following discontinuation of therapy.
  - Soriatane should be considered only for women with severe psoriasis unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments.

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe psoriasis</td>
<td>25 mg to 50 mg PO QD</td>
<td>50 mg per day</td>
</tr>
</tbody>
</table>

VI. Product Availability
Capsule: 10 mg, 17.5 mg, 25 mg

VII. References
### Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Converted to new template</td>
<td>08.15</td>
<td>08.15</td>
</tr>
<tr>
<td>Added appropriate age of use to criteria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modified approval criteria to require use of two medium to high potency topical steroid each for ≥4 weeks or use of tazarotene or calcipotriene for ≥ 8 weeks;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Added cyclosporine as an accepted preferred systemic first line agents that constitute an accepted trial;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modified criteria so that use of phototherapy with either a required topical agent or systemic agent is acceptable for approval</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Required monotherapy with phototherapy for at least 8 weeks in patients who are unable to use combination therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Updated template and references;</td>
<td>05.16</td>
<td>08.16</td>
</tr>
<tr>
<td>Change diagnosis from chronic recalcitrant to psoriasis as the definition of severe is captured by the required agent that must be trialed;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Removed requirement of Failure of two PDL medium to high potency steroids, each for ≥ 4 weeks, unless contraindicated OR Failure of ≥ 8 week trial of tazarotene or calcipotriene, unless contraindicated because that is the suggested treatment of mild to moderate psoriasis per uptodate and Menter et al; Removed requirement of “Do Your Part Program”;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Updated references</td>
<td>03.17</td>
<td>08.17</td>
</tr>
<tr>
<td>3Q 2018 annual review: increased continued approved from 6 to 12 months; references reviewed and updated, added criteria when phototherapy is unavailable.</td>
<td>04.11.18</td>
<td>08.18</td>
</tr>
<tr>
<td>3Q 2019 annual review: no significant changes; references reviewed and updated.</td>
<td>05.21.19</td>
<td>08.19</td>
</tr>
</tbody>
</table>

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering
benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2010 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.